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Innate antiviral immunity establishes first line of defense against invading pathogens
through sensing their molecular structures such as viral RNA. This antiviral potential of
innate immunity is mainly attributed to a myriad of IFN-stimulated genes (ISGs). Amongst
well-characterized ISGs, we have previously shown that antiviral potential of chicken
IFN-induced proteins with tetratricopeptides repeats 5 (chIFIT5) is determined by its
interaction potential with 5′ppp containing viral RNA. Here, we generated transgenic
chickens using avian sarcoma-leukosis virus (RCAS)-based gene transfer system that
constitutively and stably express chIFIT5. The transgenic chickens infected with clinical
dose (EID50 10
4 for HPAIV and 105 EID50 for vNDV) of high pathogenicity avian influenza
virus (HPAIV; H5N1) or velogenic strain of Newcastle disease virus (vNDV; Genotype
VII) showed marked resistance against infections. While transgenic chickens failed to
sustain a lethal dose of these viruses (EID50 10
5 for HPAIV and 106 EID50 for vNDV), a
delayed and lower level of clinical disease and mortality, reduced virus shedding and
tissue damage was observed compared to non-transgenic control chickens. These
observations suggest that stable expression of chIFIT5 alone is potentially insufficient
in providing sterile protection against these highly virulent viruses; however, it is sufficient
to ameliorate the clinical outcome of these RNA viruses. These findings propose the
potential of innate immune genes in conferring genetic resistance in chickens against
highly pathogenic and zoonotic viral pathogens causing sever disease in both animals
and humans.
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INTRODUCTION
Virus recognition by germ-line-encoded intracellular receptors underlines the potency of innate
immune responses in restricting virus infections and disease progressions (1, 2). These intracellular
receptors discriminate the host (self) nucleic acid from the virus (non-self) nucleic acid by the
presence of molecular signatures in the viral genomic material. One of the well-characterized
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signatures of innate immune induction is the presence of
triphosphate group (5′-ppp) in viral RNA which is absent in any
RNA species of the host (3). Beside canonical cellular receptors
including Toll-like receptors, retinoic-acid-inducible protein 1
(RIG-I)-like receptors, and nucleotide oligomerization domain-
like receptors, recently a novel class of IFN-effectors, known
as IFN-induced proteins with tetratricopeptides repeats (IFITs)
which has been identified to directly engage with 5′-ppp viral
RNA (4, 5).
Amongst viral RNA-recognizing cellular factors, IFITs
proteins are the most transcribed and translated family of
virus- and IFN-regulated proteins (6–8). These proteins are
evolutionary conserved with at least four well-characterized
paralogs in humans; IFIT1 (ISG56), IFIT2 (ISG54), IFIT3
(ISG60), and IFIT5 (also known as ISG58) (7–9). These IFNs
and virus-responsive proteins are implicated in the regulation of
several physiological (protein translation and cell proliferation)
and pathological (inhibition of viruses) processes in mammals
(7, 10). Among these functions, the implication of IFIT proteins
in establishing host resistance against viruses has been well
documented (4, 10, 11). Different biological, biochemical, and
structural approaches have mapped the nature of RNA that is
recognized by IFIT proteins including 5′-ppp, AU-rich elements,
and initiator tRNAs (4, 9, 11, 12). Additional evidences suggested
that IFIT5 proteins can perform their antiviral activities by
two possible ways; sequestration of viral RNA translation and
initiation of innate immune responses (9, 13). Both these
activities augment the antiviral potential of IFIT5 against RNA
viruses such as orthomyxoviruses (e.g., avian influenza viruses,
AIV) and paramyxoviruses (e.g., Newcastle disease virus,
NDV).
Highly pathogenic IAV (HPAIV) and velogenic NDV (vNDV)
are causing devastating economical and welfare impacts on
the poultry, and HPAIV are posing significant human health
implications, around the globe (14, 15). Majority of negative
sense single stranded RNA viruses, including HPIAV and vNDV,
produce 5′-ppp containing RNA during the course of virus
replication (16–18). Interaction of 5′ppp RNA and cellular
receptors (e.g., IFIT5) leads to the induction of cytokines and
may underline the antiviral state of the host with variable
clinical or pathological outcomes. Understanding host factors
that contribute in the pathobiology of viruses in their natural
hosts may help to devise effective intervention strategies and
to define the genetic markers of disease resistance. In the
present study, we investigated the in vivo impact of chicken
IFIT5 (chIFIT5) against HPAIV and vNDV-induced infections in
transgenic chickens generated by the RCAS-based retroviral gene
transfer system.
MATERIALS AND METHODS
Viruses and Virus Titration Assays (EID50)
HPAIV H5N1 (strain A/chicken/Egypt_128s_2012) and vNDV
(strain NDV-B7-RLQP-CH-EG-12 were kindly provided
by Prof Hussein Ahmed (Virology Department, Faculty of
Veterinary Medicine, Cairo University, Egypt). Both viruses
were propagated in 9 days old specific pathogen free (SPF)
chicken eggs. Infective allantoic fluid from the inoculated eggs
was diluted in brain-heart infusion buffer (BHIB) and the
median egg infectious doses 50 (EID50) were determined in SPF
eggs using the Reed and Muench method (19).
Construction of Transgene Expressing
RCAS Reverse Genetic Systems
The ORF of chicken IFIT5 was amplified from RNA extracted
from the NDV-infected primary chicken embryo fibroblasts
(CEFs), was sequence verified, codon optimized and chemically
synthesized in-fusion with V5-tag, and sub-cloned into an
improved version of RCASBP(A)-1F1 (kindly provided by
Stephen H. Hughes, National Cancer Institute, MD, USA) via
the ClaI and MulI restriction sites which replace the src gene
while maintaining the splice accepter signals. The resultant
constructs were named as RCASBP(A)-chIFIT5. Similarly, a
GFP encoding RCASBP(A), referred as RCASBP(A)-eGFP,
was generated by introducing the coding sequence of the
GFP in between the ClaI and MulI sites. The inserted gene
orientation and sequence validity were confirmed by DNA
sequencing.
Rescue of RCAS Viruses and Validation of
Transgene Expression
To rescue recombinant RCASBP(A) viruses, a total of 2.5 × 105
DF-1 cells were seeded in 25 cm2 flasks and maintained at 37◦C,
5% (vol/vol) CO2 for 24 h (∼80% confluent). Cells were washed
with PBS and transfected with 2.5 µg of each of the RCASBP(A)-
eGFP, and RCASBP(A)-chIFIT5 plasmids using Lipofectamine
2000 in OptiMEM with a pre-determined optimized ratio of
1:6 (Invitrogen, Carlsbad, CA, USA). Media were changed 6 h
post transfection and the cells were maintained in DMEM
supplemented with 10% FCS and 1% penicillin/streptomycin
for 48 h. Expression of the reporter gene (GFP) was monitored
using fluorescence microscopy whereas replication efficiencies
of chIFIT5 expressing retroviruses were assessed by staining
the structural protein of RCASBP(A) and V5 tag. The GFP/gag
expression-confirmed cell cultures were split into 25 cm2 flasks
and were passaged again into 75 cm2 flasks after 3 days. Finally,
cells were expanded into 150 cm2 flasks until the desired number
(106 cells/egg) was achieved.
Confocal Microscopy
Chicken cells were transfected with individual or combined
plasmids for indicated time points using Lipofectamine 2000
(Invitrogen) at a ratio of 1:3 or were infected with lentiviruses,
retroviruses or NDV-GFP for indicated time points. These
cells were then fixed for 1 h in 4% paraformaldehyde and
permeabilised using 0.1% Triton-X100 before incubation with
primary antibodies raised against V5 tag, or gag protein of
retroviruses. Additionally, depending upon the experimental
needs, different fluorescent markers (RFP, GFP) were used.
Afterwards, cells were incubated with corresponding secondary
antibodies at 37◦C for 2 h. After brief staining with 4′, 6-
diamidino-2-phenylindole (DAP1) (nuclear), slides were
visualized using a Leica SP5 confocal laser-scanning microscope.
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Animals
SPF eggs were acquired from a local supplier in co-operation
with Virology Department, Faculty of Veterinary Medicine,
Cairo University, and the Central Lab for Evaluation of
Veterinary Biologics Abbassia, Egypt. Transgenic chickens were
generated as described below and each group of birds was
housed separately at containment level 4 isolators. Food and
water were provided ad libitum, and general animal care
was provided by the animal house staff as required for each
groups.
Generation of Transgenic Chickens
Mosaic-transgenic chicken embryos were generated by
inoculation of 1 million RCASBP(A)-chIFIT5-infected DF-
1 cells or non-infectious DF-1 cells using 24G needs at day 2
post-embryonation in SPF chicken eggs. Embryos were fixed
for 2 h post-inoculation before incubation at 37◦C with 60–80%
humidity in rotating incubator (twice daily). Transgenic embryos
were allowed to hatch naturally at 21 days of incubation or were
manually hatched on 22 days of embryonation.
Challenge Experimental Design
Experiment 1: Virus Dose Optimization
To effectively monitor the dose of viruses that can either
induce clinical signs or mortality, a total of 10 SPF chicks
(12 days old) were individual challenged with a dose of 104,
105, 106 EID50 of HPAIV-H5N1. Similarly, vNDV was used to
challenge 10 SPF chicks with a dose of 104, 105, 106 EID50 in
isolation units under biosafety level 4 conditions, and disease
was monitored in all groups for 11 days for the appearance
of clinical signs, weight gain, feed intake and mortalities in all
groups. Birds were monitored for the presence of clinical sign
and symptoms twice daily which were recorded as clinical scores
1 (no clinical signs), 2 (mild clinical signs), 3 (severe clinical
signs), or 4 (dead/mortalities), as described previously (20, 21).
At day 11 post-infection, the remaining animals were humanly
euthanized.
Experiment 2: Transgenic Chickens and Virus
Challenge
A total of 11 RCASBP(A)-chIFIT5 transgenic chicks
(chIFIT5-HPAIV/vNDV +ve), 20 mock-inoculated chicks
(mock-HPAIV/vNDV +ve) were either challenged with 104
EID50 HPAIV or 10
5 EID50 vNDV (clinical doses) on 12
days of age (1st day virus infection). Correspondingly, 10
chicks were kept as a naïve control group that were neither
inoculated with retroviruses nor challenged with HPAIV or
vNDV (mock-HPAIV/vNDV –ve). Before second challenge, a
naïve group (Naïve-HPAIV/vNDV +ve) containing 4 chicks
for HPAIV group and 3 chicks for NDV group was introduced.
Except mock-HPAIV/vNDV –ve, individual birds in all groups
were challenged with 106 EID50 of HPAIV and vNDV. Disease
was monitored for next 10 days for the appearance of clinical
signs, weight gain, feed intake and mortalities in all groups.
Birds were monitored for the presence of symptoms twice
daily, and clinical signs were recorded as clinical scores 1
(no clinical signs), 2 (mild clinical signs), 3 (severe clinical
signs), 4 (dead), as was described previously (20). Three birds
from chIFIT5-HPAIV/vNDV +ve and two chicks from mock-
HPAIV/vNDV +ve were sacrificed for comparison between
transgenic and wild type birds. The experiment was terminated
at day 17 post-challenge and all remaining animals were
euthanized.
Confirmation of Transgene Expression
Total RNA was extracted from trachea, which were collected
from transgenic and non-transgenic chickens using TRIzol
reagents (Invitrogen, Carlsbad, CA, USA). A total of 200 ng
of RNA was used in PCR reactions using SuperScript R© III
Platinum R© SYBR R© Green One-Step qRT-PCR Kit (Invitrogen,
Carlsbad, CA, USA) as we demonstrated earlier (5). The
abundance of specific chIFIT5 mRNA was compared to the
28S rRNA in the Applied Biosystems Prism 7500 system. The
reaction was carried out using the thermo profile reported
earlier (5).
Expression of Innate Immune Genes
In order to determine the expression of innate immune genes,
total RNAwas extracted as described above using TRIzol reagents
(Invitrogen, Carlsbad, CA, USA). A total of 200 ng of RNA
was used in PCR reactions using SuperScript R© III Platinum R©
SYBR R© Green One-Step qRT-PCR Kit (Invitrogen, Carlsbad,
CA, USA). The abundances of specific innate immune gene
mRNA in trachea from transgenic (n = 05) and non-transgenic
(n= 05) from both virus (HPAIV and vNDV) andmock-infected
birds were compared to corresponding 28S rRNA and the average
fold changes were determined (Supplementary Table 1). The
reaction was carried out in ABI 7500 light cycler using the thermo
profile described earlier (5). Primers for innate immune genes are
provided in Supplementary Material.
Processing of Swab Samples
Cloacal and oropharyngeal swabs were collected in 1mL of 15%
BHIB with antibiotics (10,000 IU/mL Penicillin G + 100µg/mL
Gentamycin+ 20µg/mL Amphotericin B) and were kept on ice,
and then filtered through a 0.2µmfilter. The filteredmaterial was
stored at −80◦C until all samples were collected, and then were
subjected to HA as described previously (22).
Histopathology
Selected tissues including trachea, brain, spleen, kidney and
liver were collected and fixed by immersion in 10% neutral
buffered formalin at room temperature for 48 h followed by
processing and embedding in paraffin wax. Tissue sections of
5µmwere stained with Haematoxylin & Eosin and examined for
microscopic lesions under light microscope.
Statistical Analysis
Pairwise comparisons of treated and control groups were
performed using Student’s t-test. Kaplan-Meier analysis was
performed to calculate the survival rates. All statistical tests were
conducted in the GraphPad Prism 7 (GraphPad Software, La
Jolla, CA, USA).
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Ethics Statement
All animal studies and procedures were carried out in strict
accordance with the guidance and regulations of European
and United Kingdom Home Office regulations. As part of this
process, the work has undergone scrutiny and approval by the
Animal Welfare and Ethical Review Body (AWERB) at The
Pirbright Institute, UK.
RESULTS
Effective and Constitutive Expression of
Transgene Using RCAS Vector System
We have recently demonstrated that chicken IFIT5 is a crucial
host restriction factor and can effectively subvert the replication
of negative sense single stranded RNA viruses in vitro and in
ovo (5). We next sought to investigate the potential of this
antiviral protein in interfering virus replication in vivo and to
propose a genetic marker of resistance against RNA viruses
in poultry. For this purpose, efforts were made to generate
transgenic chickens stably expressing chIFIT5, and to determine
the antiviral potential of chIFIT5. For this purpose, we applied
avian retroviruses (avian leukosis virus, ALV) vector-based
expression system to assess impact of chIFIT5 gene against virus
challenges in developing chicks. Specifically, the replication-
competent and avian-origin RCAS (replication competent ALV
long terminal repeats with a splice acceptor) system was
applied to generate mosaic transgenic chicken (20, 23). The
transgenes (GFP and chIFIT5) were expressed by the splice
acceptor (SA) signal of the src viral oncogene, which were
inserted between the unique polylinker sites as depicted in
Figure 1A.
Initially, a reporter virus construct (RCASBP(A)-eGFP)
was generated to monitor in vitro rescuing and progression
of the virus. In addition, we constructed RCASBP(A)-
chIFIT5 recombinant virus to generate mosaic-transgenic
chicken embryos that are constitutively expressing chIFIT5.
FIGURE 1 | Generation and rescue of recombinant retroviruses expressing marker gene (GFP), and chIFIT5. (A) A schema for the generation of recombinant RCAS
viruses in which src gene was replaced with either GFP, or chIFIT5. (B) Retroviruses were rescued in DF-1 cells and stained for retroviral structural gag protein and
V5-taged fused to the chIFIT5, indicating the specific replication-competency of these retroviruses. (C) Immunofluorescence staining of the transgene in chicken
fibroblasts expanded from individual clones expressing RCAS-mediated GFP and IFIT5 indicating stable and substantial expression of these proteins.
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Both viruses were rescued in chicken embryo fibroblasts
(DF-1) and replication was assessed by monitoring viral
structural protein (gag) and transgene; GFP and V5-tagged
chIFIT5, simultaneously (Figure 1B). Cell clones expressing
RCAS-mediated GFP and chIFIT5 were individually and clonally
expanded to obtain require stock density for transgenic embryo
generation. Immunofluorescence staining of the transgene in
chicken fibroblasts (Figure 1C) indicate stable and substantial
expression of these proteins. These validated infectious
chicken fibroblasts were used to generate transgenic chicken
embryos.
Clinical and Lethal Dose Assessment for
HPAIV and vNDV
HPAIV and vNDV strains cause severe infections and the
clinical outcome of infection depends upon several factors
including nature of the virus and genetics of the host (24).
Based on the surface glycoprotein genes (haemagglutinin (HA)
and fusion (F) genes), influenza and NDV can be divided into
different subtypes, pathotypes, clades (Figure 2A) and genotypes
(Figure 2B), respectively. Viruses belonging to H5-subtype that
possess polybasic residues at the hemagglutinin protein cleavage
site are reported to be highly pathogenic for both chickens
and human (15), whereas Genotype VII strains of NDV are
most prevalent and one of the major pathogen for clinical ND
infections in chickens, around the globe (14).
Owing to direct correlation of virus dose with the severity
of the clinical infections, we first determined the titre of
HPAIV and vNDV inoculum, which induce clinical disease
in chickens. Groups of ten SPF-chickens (12 days old) were
challenged with different dosses (104, 105, or 106 EID50) of
HPAIV or vNDV and clinical disease scores were recorded until
11 days post-infection. Based on the level of disease severity,
104 EID50 inoculum of H5N1 HPAIV induced clinical signs
and was therefore considered as clinical dose. However, rapid
death (lethal dose) was observed in birds inoculated with 106
EID50 dose of H5N1 HPAIV (Figure 2C). For vNDV, most
clinical signs were observed when 105 EID50 virus particles
(clinical dose) were used whereas a substantial mortality was
observed in chickens, which were inoculated with 106 EID50
virus dose (lethal dose) (Figure 2D). Prototype strains of H5N1
clade 2.2.1.2 (A/chicken/Egypt_128s_2012) and vNDV genotype
VIId (NDV-B7-RLQP-CH-EG-12) with optimized doses 104
EID50 and 10
5 EID50 were used as inoculum to challenge
transgenic chickens to demonstrate antiviral potential of
IFIT5.
Improved Survivability of Transgenic
Chickens Expressing ChIFIT5 Following
Infection With HPAIV and vNDV
Mosaic transgenic chickens were generated by inoculating 2-
day-old embryonated SPF eggs with recombinant RCAS virus-
infected CEF expressing chIFIT5 (as shown in Figure 1C) or
were inoculated with non-infectious CEF. Chicks hatched from
infected embryonated eggs were reared in isolators until 12
days of age before challenge with clinical dose of HPAIV or
vNDV at 12 days of age followed by lethal dose on 20 days
of chick’s age (8 days post first infection) (Figure 3A). Onset
of clinical disease and health parameters were assessed until
the end of experiment in IFIT5-expressing virus-challenged
(chIFIT5-HPAIV/vNDV +ve), mock-inoculated and virus-
challenged (mock-HPAIV/vNDV +ve) and mock-inoculated
and non-virus-challenged groups (mock-HPAIV/vNDV –ve).
Additionally, in order to delineate priming effect of clinical dose
of the virus on the lethal dose, a naïve SPF group of chicken was
included and challenged with lethal dose only.
While no detrimental effect of the chIFIT5 expression
was observed on the embryonic development, hatchability of
RCAS-chIFIT5 transgenic eggs was compromised compared to
mock groups in two independently performed experiments.
A total of 3 manually hatched and 6 naturally hatched
chicks in RCAS-chIFIT5 group were weak and unhealthy,
unable to drink, dehydrated and shown visceral gout, and
all were humanly euthanized due to welfare reasons before
the clinical challenge (12 days of hatching). No further
macroscopic lesions or pathologies were noticed on necropsy
investigation of these euthanized birds (data not shown).
Interestingly, all RCAS-chIFIT5 transgenic chicks were hatched
with substantially reduced body weight (Figure 3B). Except
chicks (n = 6) that were died at 2nd, 7th or 9th day
of hatching, RCAS-chIFIT5 transgenic chicks progressively
regained the body weight and shown comparable weight with
mock controls before first virus challenge at day 12 post hatch
(Figure 3C).
A total of 30% mock-inoculated chicks were succumbed
to HPAIV infection within 4 days of infection. However,
RCAS-chIFIT5 transgenic chicks were fully protected with
the clinical dose of HPAIV (chIFIT5-HPAIV +ve) as was
observed in negative control (Mock-HPAIV –ve) (Figure 3D).
Correspondingly, overexpression of IFIT5 protected all birds
whereas 90% mock-inoculated chickens showed no apparent
clinical disease when inoculated with clinical dose of vNDV
(Figure 3E). In comparison, the group challenged with lethal
dose of HPAIV showed rapid and sever disease signs and
were humanly euthanized. Suggesting lethal dose of HPAI
override endogenous levels of host innate responses including
overexpression of IFIT5 (Figure 3F). Albeit corresponding
mortality was observed in chicks challenged with lethal dose
of vNDV, the lethality of the virus was meliorated for 4
days in RCAS-chIFIT5 transgenic chicks (Figure 3G). In order
to exclude the possibility of priming effect of clinical dose
on the protective efficacy of IFIT5 against lethal dose, naïve
chicks of same age were challenged with corresponding lethal
doses of HPAIV and vNDV (Naïve-HPAIV/vNDV +ve). As
expected, 100% HPIAV and 66% vNDV challenged naïve chicks
showed sever clinical signs and were culled or suddenly died
due to infection within three days of challenge (Figures 3F,G).
Taken together, the results demonstrate the functional role
of IFIT5 to progressively protect chicks from clinical doses
of both RNA viruses; however, overexpression of IFIT5 is
insufficient as a stand-alone antiviral host factor that could
completely protect chickens from the lethal dose of HPAIV and
vNDV.
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FIGURE 2 | Strain selection and clinical and lethal doses assessment for HPAIV and vNDV. (A) Bioinformatics analysis of representative strains of H5N1 and (B)
velogenic strains of NDV. Strains used in this study are colored gray. (C) Twelve days old SPF-chickens were challenged with the EID50 of 10
4, 105, and 106 HPAIV or
(D) vNDV and the disease was monitored until 11 days post-infection. Color gradient represent the severity of clinical signs.
Transgenic Chickens Expressing ChIFIT5
Showed Protection From Clinical Disease
Signs When Challenged With Sub-lethal
Dose of HPAIV and vNDV
Intriguingly, IFIT5 fully protected transgenic chicks frommorbid
clinical signs when exposed to sub-lethal dose (104 EID50)
of HPAIV (Figure 4). In contrast, mock group (Mock-HPAIV
+ve) showed sever clinical signs as early as third day following
inoculation with clinical virus dose (104 EID50). The clinical signs
were further exacerbated when birds were follow-on exposed to
lethal dose of HPAIV. While chicks in negative control (Mock-
HPAIV –ve) remained healthy and corresponding challenged
group shown the most clinical signs, overexpression of IFIT5
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FIGURE 3 | Generation of transgenic chickens and impact of chIFIT5 on physiological parameters of chicken. (A) Schema representing the time of transgenesis and
challenge experiment. (B) Comparison of the body mass of chIFIT5 expressing transgenic chicken and control chicken. (C) Wait gain in transgenic and control
chickens post-hatching and pre-challenge. (D) Survival curve of chickens against clinical dose of HPAIV, (E) vNDV, (F) lethal dose of HPAIV and (G) vNDV.
has substantially reduced the appearance of the clinical outcomes
of HPAIV infections. These effects were markedly observed
in vNDV infected RCAS-chIFIT5 transgenic chicks. Not only
that IFIT5 expressing chicks were protected from the clinical
challenge but substantially from the lethal challenge (Figure 4).
Importantly, the clinical signs, which appeared in the RCAS-
chIFIT5 transgenic chicks, were delayed by at least by 10 days
(Figure 5). These results highlight the possible roles of IFIT5 in
meliorating the clinical outcome of two highly pathogenic viruses
in the poultry, influenza and NDV.
Confirmation of Transgene Expression and
Reduced Virus Shedding in
IFIT5-Expressing Transgenic Chickens
Challenged With HPAIV and vNDV
In order to demonstrate the successful expression of chIFIT5 in
transgenic chickens, we exploited the codon-optimized version
of RCAS-mediated chIFIT5 gene (5). A quantitative PCR that
specifically detect codon-optimized chIFIT5 was established
to demonstrate the expression of chIFIT5 as transgene and
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FIGURE 4 | Clinical signs of individual chicken in different groups pre- and post-clinical and lethal challenge induced by the HPAIV.
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to differentiate the transgene from endogenously expressed
chIFIT5. Using this assay, we detected a significantly higher
level of IFIT5 in tracheal RNA collected from transgenic chicken
compared to corresponding non-transgenic RNA. Relative to
HPAIV-infected transgenic chicken (Figure 6A), the expression
of chIFIT5 was significantly higher in vNDV-infected transgenic
chickens (Figure 6B). Collectively, these data demonstrate the
successful generation of transgenic chicken and the expression of
transgene.
We next assessed if chIFIT5-mediated reduction in the
clinical picture reflect upon the virus shedding in two most
common routes of virus transmission and shedding; oral and
cloacal routes. For this purpose, both cloacal and oropharyngeal
swabs were collected from all three groups (chIFIT5-vNDV+ve,
and mock-vNDV +ve, and mock-vNDV –ve) before the
challenge and every day post-clinical and post-lethal dose
challenges. Assessment of virus titres in the swab samples
indicated a substantial shedding of both vNDV and HPAIV in
cloacal secretions (Figures 6C,D). However, transgenic chickens,
constitutively expressing chIFIT5 showed substantial reduction
in both shedding titres (NDV: 8 log2 vs. 4 log2 in control, HPIAV;
3 log2 vs. 12 log2 in control) and the duration of shedding period
following challenge with vNDV and HPAIV. In comparison to
vNDV challenged chickens, the virus shedding was markedly
reduced in cloacal swabs of HPAIV-challenged chicks.
Since shedding of both under-study viruses reported by the
respiratory route of the chicken (22), we next assessed the
magnitude of virus shedding in oropharyngeal swabs. Virus
quantification analysis indicated secretion of both viruses (vNDV
and HPAIV) in mock-transgenic and viruses-infected animals.
However, intriguingly, the shedding of the viruses was fully
blocked in chickens, which were engineered to constitutively
express chIFIT5 in both clinical and lethal doses challenge
(Figures 6E,F). A relatively low surge in virus shedding (1 log2)
was observed in chickens that were challenged with lethal dose of
HPAIV, which was subsided in 2 days. Collectively, these finding
suggest that chIFIT5 play decisive roles in virus replication
especially in the respiratory epithelial cells resulting in lower
shedding levels in of viruses in the buccal cavity.
The ChIFIT5-Expressing Transgenic
Chickens Show Improved Virus-Induced
Microscopic Pathologies and These Are
Not Associated With Enhanced Innate
Immunity
In order to estimate the magnitude of histopathological changes
induced by these pathogenic viruses and the level of protection
afforded by the stably expressing chIFIT5, organs (trachea, brain,
spleen, kidneys and liver) were collected and histopathologically
examined both at the clinical and lethal doses and compared
with non-treated and mock controls. As expected, examination
of trachea showed marked pathological lesions in mocked-
transgenic and HPAIV and vNDV-challenged chickens including
focal necrosis of lamina epithelialis mucosa, oedema in the
lamina propria and congestion of mucosal blood vessels (after
clinical-challenge). Severe histopathological alterations were also
noticed after lethal-challenge including focal necrosis of the
mucosa and accumulation of mucous exudate in the tracheal
lumen. On the other hand, trachea collected from chickens,
which were transgenically expressing chIFIT5 and infected
with HPAIV and vNDV showed no histopathological changes
except slight congested blood vessels, slight edema in the
lamina propria/submucosa layers (Figures 7A–T). Congestion of
cerebral blood vessel, necrosis of neurons and neuronophagia
were observed in brain collected from mocked-transgenic and
vNDV and HPAIV-challenged chickens. In brain examined
from chicken, which were transgenically expressing chIFIT5 and
infected with vNDV and HPAIV, showed lesions of slight cellular
oedema and necrosis of sporadic neurons (Figures 7A–T).
Corresponding histopathological lesions were observed in
spleen, kidneys and liver (Supplementary Figure 1). Taken
together, these results demonstrate that constitutive expression of
chIFIT5 protects different organs against virus replication, which
collectively reflect upon virus shedding, ameliorated clinical
outcome and improved health status.
Owing to association of IFIT5 mediated induction of innate
immunity (10, 13), we next investigated whether the improved
protection in transgenic chickens was mediated by the innate
immunity. For this purpose, total RNA was extracted from
trachea, because both viruses can cause respiratory signs, and
expression levels of five innate immune genes were determined.
These genes were chosen based on their expression dynamics
against viruses, and existing assays (1). Direct comparison of
expression of innate immune genes indicated non-significant
differences between transgenic (over-expressing chIFIT5) and
non-transgenic (mock expressing) (Supplementary Table 1).
These differences were not only noticed in vNDV challenged
birds, which show enhanced protection but also in HPAIV-
challenged birds, that were susceptible to influenza infections.
These results propose that chIFIT5-confered protection was not
associated with the induced innate immune responses and may
link to direct antiviral affect of chIFIT5 (5, 9).
DISCUSSION
Poultry production is crucial for economy and food security
for growing global human population. While the productivity
of poultry has increased significantly over the years through
selective breeding and improved genetics, the threats imposed by
emerging and re-emerging pathogens have increased significantly
especially since the introduction of intensive poultry-raising
systems (25). Among these pathogens, avian viruses are at
the forefront of constraints to enhanced productivity including
avian influenza virus, NDV and infectious bronchitis virus
amongst others. Upon infection with viruses, the innate immune
responses mainly mediated by IFN-regulated proteins establish
profound antiviral state in the host, and defines the gravity
clinical disease outcome and associated decrease in productivity
and mortalities. Avian species, especially chicken, are unique in
the nature and dynamics of innate immunity (1) and are known
to play crucial roles in the evolution and emergence of influenza
viruses and their potential to cause infections in human (26).
Interestingly, chickens are lacking essential components of
innate immune system (e.g., RIG-I, IRF3, IRF9); they yet mount
profound innate immune responses against virus infections
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FIGURE 5 | Clinical signs of individual chicken in different groups pre- and post-clinical and lethal challenge induced by the vNDV.
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FIGURE 6 | Expression of the transgene (chIFIT5), in vNDV-infected transgenic (A) and HPAIV-infected transgenic (B), compared to non-transgenic chicken.
Quantitative assessment of virus shedding in cloacal section for the (C) vNDV, (D) HPAIV and in oropharyngeal secretion for the (E) vNDV and (F) HPAIV in transgenic
chickens expressing chIFIT5-challenged with virus (chIFIT5-vNDV/HPAIV +ve), mock-transgenic-virus challenged (mock-vNDV/HPAIV+ve) and mock control
(mock-vNDV/HPAIV –ve). Days of clinical and lethal challenges are marked with arrows. *** indicate the level of significance at p > 0.05.
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FIGURE 7 | (A) Trachea of chicken infected with HPAIV (clinical challenged) showing focal necrosis of lamina epithelialis (small arrow) and oedema in the lamina
propria/submucosa layer (large arrow). (B) Trachea of chicken expressing chIFIT5 and infected with HPAIV showing slight congested blood vessel. (C) Trachea of
chicken infected with vNDV (clinical challenged) showing activation of mucous secreting glands (small arrow) and oedema in the lamina propria/submucosa layers
(large arrow). (D) Trachea of chicken expressing chIFIT5 and infected with vNDV showing slight oedema in the lamina propria/submucosa layers. (E) Trachea of control
chicken showing the normal histological layers. (F) Trachea of chicken infected with HPAIV (lethal challenged) showing focal necrosis of the mucosa (small arrow) and
accumulation of mucous exudate in the lumen (large arrow). (G) Trachea of chicken injected expressing chIFIT5 and infected with HPAIV (lethal challenge) showing
oedema in the lamina propria/submucosa layers. (H) Trachea of chicken infected with vNDV (lethal challenge) showing necrosis of the mucosa (arrow). (I) Trachea of
chicken expressing chIFIT5 and infected with vNDV (lethal challenge) showing congested blood vessels. (J) Trachea of control chicken showing the normal histological
layers. (K) Brain of chicken expressing chIFIT5 and infected with HPAIV (clinical challenge) showing congestion of cerebral blood vessel (small arrow) and necrosis of
neurons (large arrow). (L) Brain of chicken expressing chIFIT5 and infected with HPAIV (clinical challenged) showing no histopathological changes. (M) Brain of chicken
expressing chIFIT5 and infected with HPAIV (clinical challenged) showing necrosis of neurons (arrow). (N) Brain of chicken expressing chIFIT5 and infected with vNDV
(clinical challenge) showing cellular oedema. (O) Brain of control chicken showing no histopathological changes. (P) Brain of chicken expressing chIFIT5 and infected
with HPAI (lethal challenge) showing congestion of cerebral blood vessel (small arrow) and necrosis of neurons (large arrow). (Q) Brain of chicken expressing chIFIT5
and infected with HPAIV (lethal challenged) showing no histopathological changes. (R) Brain of chicken expressing chIFIT5 and infected with vNDV (lethal challenged)
showing necrosis of neurons and neuronophagia (arrow). (S) Brain of chicken expressing chIFIT5 and infected with vNDV (lethal challenged) showing necrosis of some
neurons and neuronophagia. (T) Brain of control chicken showing no histopathological changes. (All images were stained with H&E and are imaged at x400).
(1). Efforts have been made to delineate underlying molecular
factors that uniquely control the virus-mediated innate immune-
induction and have provided mechanistic insights, which
differ between avian and mammals. Further understanding the
alternative means immune regulation and antiviral defenses
in chicken could establish the foundation to control avian
viral disease and the chicken-mediated emergence of zoonotic
infections such as influenza viruses (26).
Recently, in an effort to explore the functional implication
of IFIT proteins in chickens, we reported that chicken encodes
single IFIT5 proteins compared to several in humans and mice.
This highly virus- and IFN-inducible protein interacted with
RNA carrying a triphosphate group on its 5′ terminus (ppp-RNA)
(5). These structures are present in the native form of negative
sense viral genomics RNA. It is hypothesized that the interaction
of IFIT5 with the 5′-ppp containing viral RNA potentially
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interferes with the transcription and subsequent translation
of viral proteins (5). These interferences cooperatively impact
negatively on the replication kinetics of RNA viruses. Most of
these studies we conducted either in the cell culture models or
in ovo, highlighting the potential of chIFIT5 as essential host
antiviral restriction factor. To further investigate the antiviral
activity of IFIT5 in vivo, we generated mosaic transgenic chicken
that stably and constitutively express chIFIT5. These chickens
were used to test the antiviral impact of IFIT5 on two highly
pathogenic viruses; HPAIV and vNDV.
The mosaic transgenic chickens overexpressing chIFIT5
provided strong evidences that this cytokine possesses profound
antiviral activities in vivo. These antiviral actions were sufficient
to fully protect chicken against dose of viruses that otherwise
cause clinical disease signs in chickens. Since the virus load
in the field condition varies and the exposure of chickens to
environmental stress contributes to the virus-induce pathologies,
we additionally assess the impact of chIFIT5 overexpression on
the pre-determined lethal dose (an amount virus dose that cause
server disease and mortality in chickens). While over expression
of chIFIT5 alone seems insufficient in affording complete
protection from morbidity and mortality when challenged with
“lethal dose (105-106 EID50)” of viruses. Nevertheless, the clinical
outcome was substantially ameliorated when transgenic chickens
were challenged with “clinal dose 104-105 EID50.” Furthermore,
the results clearly ruled out the possibility that pre-exposure with
“clinical dose” may have induced adaptive immune responses
masking the impact of “lethal dose” on clinical outcome. These
evidences clearly highlight the potential of innate immune in
conferring resistance against HPAIV and vNDV.
It is noteworthy to mention that the protective role of
chIFIT5 was assessed against two highly virulent viruses; highly
pathogenic IAV and velogenic NDV. Both can cause up to
100% mortality in infected flocks. Therefore, it is plausible
to hypothesize that the chIFIT5-alleviated morbidity against
these highly pathogenic viruses may propose relatively profound
impacts against viruses that are relatively less virulent, cause only
clinical disease and low mortality. Additionally, vaccination of
chIFIT5-expressing transgenic chicken may provide additional
resistance to viruses, which warrant future investigation.
The challenge to generate transgenic chickens was mitigated
by the use of RCAS-based retroviral gene transfer system.
Based on previous studies (20, 27) and our recent report (5),
retroviral-mediated transgene expression has been proposed as
a convenient, economical and less laboratory-intensive system.
Our in vitro investigation and in ovo assessments further
confirmed the expression of transgenes in developing embryos
and chicks. Additionally, we used qPCR to specifically detect
chIFIT5 in tracheal RNA which is not only demonstrating the
successful transgenesis but also re-enforcing our previous finding
(5) that dictate the predominant expression of RCAS-mediated
gene delivery in epithelial-enriched organs. While the RCAS-
vector system is an efficient approach, it is by nomeans substitute
for the genome edited-based (TALEN or CRISPR) transgenesis.
It is therefore feasible that the phenotypic effect of chIFIT5 as
antiviral may be profound in knocked-in primordial germinal
cells and CRISPR/Cas9-generated transgenic chickens.
Overexpression of chIFIT5 has not only alleviated the
manifestation of clinical disease signs in HPAIV and vNDV
infected chickens but also reduced the viruses-induced
pathological lesions and virus shedding. Since RCAS-based
retroviral gene transfer system is predominantly effective in
organs that are rich in endothelial cells (20, 27), we reasoned the
complete blockage of virus shedding in trachea. This substantially
reduced virus shedding correlated with the improved tracheal
tissue health, which may highlight the expression and functional
importance of chIFIT5 in mucosal surfaces. However, further
investigations are warranted to ensure the enriched expression
of this host factor in tracheal lining and its subsequent impact
on virus replication. While a reduced body weight in transgenic
chicks at hatching was observed, hatched chicks regained the
weight swiftly and obtained comparable sizes to non-transgenic
chicks. It requires additional investigations to fully delineate
the mechanisms of this retarded embryo development; there
are feasibilities that transgenically over-expression of the IFIT5
may interfere physiological and developmental processes of the
chick. A single IFIT5 in chicken, compared to four or more in
mammals, may likely to be restricted with its biological activities
or may propose unconventional functions, which require future
investigations.
Since previous reports (10, 13) indicate that human IFIT5
can positively regulate innate immune responses and hence
inhibits viruses, wemapped chicken innate immune genes (n= 5;
Mx, IFN-β, Viperin, IFI35, ADAP2) in transgenic chickens that
were over-expressing chIFIT5. A non-significant difference was
observed between transgenic and non-transgenic chicken. These
finding propose existence of additional mechanisms that dictate
the antiviral actions of chIFIT5 such as interaction with 5’-
RNA and sequestration of viral RNA (5, 9, 10). Moreover, due
to missing of additional IFIT genes in chicken (5), it is also
plausible that chicken IFIT5 might carry functional plasticity
for antiviral activities compared to human IFIT5, which require
further research to delineate these mechanisms.
Taken together, we characterized the function of chIFIT5
in chicken and systemically analyzed the functional rationale
for antiviral activities of chIFIT5 against RNA viruses using
transgenic animal model. These finding propose the potential
of innate immune in conferring resistance in chicken against
viruses and provide evidences to generate future virus-resistance
transgenic chicken for food security and to hamper transmission
of zoonotic viruses to human.
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